IMVT - NASDAQ

Immunovant, Inc.

IMVT·NASDAQ

$31.15

+1.2%

HealthcareBiotechnology

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.40B

EPS-2.7700

P/E Ratio-11.25

Earnings Date06/04/2026

imvt

Shares Outstanding

Last Annual Value

182.42M

3-Year CAGR

14%

5-Year CAGR

16%

10-Year CAGR

34%

Adjust for Inflation

Immunovant, Inc. Competitors Analysis of shares-outstanding

IMVT · NASDAQ

Company	shares-outstanding	CAGR 3Y	CAGR 5Y	CAGR 10Y
Immunovant, Inc. NASDAQ:IMVT	182.42M	14.0%	15.8%	N/A
Soleno Therapeutics, Inc. NASDAQ:SLNO	54.33M	48.8%	59.2%	74.6%
Kymera Therapeutics, Inc. NASDAQ:KYMR	84.39M	13.1%	12.0%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	112.67M	6.1%	7.9%	21.3%
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	98.60M	10.3%	7.8%	9.6%
Dyne Therapeutics, Inc. NASDAQ:DYN	128.44M	29.1%	20.3%	-0.0%
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD	171.36M	1.5%	1.3%	4.0%
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	94.06M	17.4%	19.6%	21.1%
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS	114.40M	11.7%	45.2%	N/A
Akero Therapeutics, Inc. NASDAQ:AKRO	67.14M	8.5%	14.0%	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	22.50M	50.6%	51.4%	N/A

Immunovant, Inc. Fair Value Envelope

IMVT · NASDAQ

Our analysis suggests that IMVT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $31.15, this represents a potential HIDDEN relative to our calculated worth for Immunovant, Inc..

HIDDEN

Intrinsic Value

Current Price: $31.15

Related Guides

Blog Categories

Continue your IMVT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.